Publications by authors named "David Coeffic"

Claim this Profile
R
Real-World Data on Olaparib in Relapsed BRCA-mutated Ovarian Cancer: A Multicenter GINECO RETROLA Cohort Study.
Heloïse Bourien, Leïla Bengrine Lefevre, Marie-Ange Mouret-Reynier, Bernard Asselain, Brigitte Lucas, David Coeffic

Anticancer Res· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification of Neoadjuvant Chemotherapy Response in Muscle-Invasive Bladder Cancer by Fourier-Transform Infrared Micro-Imaging.
Camille Mazza, Vincent Gaydou, Jean-Christophe Eymard, Philippe Birembaut, Valérie Untereiner, David Coeffic

Cancers (Basel)· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term outcomes in patients with PET-predicted poor-responsive HER2-positive breast cancer treated with neoadjuvant bevacizumab added to trastuzumab and docetaxel: 5-year follow-up of the randomised Avataxher study.
Bruno Coudert, Jean-Yves Pierga, Marie-Ange Mouret-Reynier, Kaldoun Kerrou, Jean-Marc Ferrero, David Coeffic

EClinicalMedicine· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Real-life study of 7-year survival in patients treated with trastuzumab for HER2+ early breast cancer].
Mahasti Saghatchian, Elsa Curtit, David Coeffic, Alain Flinois, Christelle Levy

Bull Cancer· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
UCBG 2-08: 5-year efficacy results from the UNICANCER-PACS08 randomised phase III trial of adjuvant treatment with FEC100 and then either docetaxel or ixabepilone in patients with early-stage, poor prognosis breast cancer.
Mario Campone, Magali Lacroix-Triki, Lise Roca, Marc Spielmann, Hans Wildiers, David Coeffic

Eur J Cancer· November 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and efficacy of single-agent bevacizumab-containing therapy in elderly patients with platinum-resistant recurrent ovarian cancer: Subgroup analysis of the randomised phase III AURELIA trial.
Roberto Sorio, Célia Roemer-Becuwe, Felix Hilpert, Emma Gibbs, Yolanda García, David Coeffic

Gynecol Oncol· January 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Use of [(18)F]-FDG PET to predict response to neoadjuvant trastuzumab and docetaxel in patients with HER2-positive breast cancer, and addition of bevacizumab to neoadjuvant trastuzumab and docetaxel in [(18)F]-FDG PET-predicted non-responders (AVATAXHER): an open-label, randomised phase 2 trial.
Bruno Coudert, Jean-Yves Pierga, Marie-Ange Mouret-Reynier, Kaldoun Kerrou, Jean-Marc Ferrero, David Coeffic

Lancet Oncol· December 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Can treatment with Cocculine improve the control of chemotherapy-induced emesis in early breast cancer patients? A randomized, multi-centered, double-blind, placebo-controlled Phase III trial.
David Pérol, Jocelyne Provençal, Anne-Claire Hardy-Bessard, David Coeffic, Jean-Phillipe Jacquin

BMC Cancer· December 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adjuvant docetaxel/cyclophosphamide in breast cancer patients over the age of 70: results of an observational study.
Gilles Freyer, Mario Campone, Julien Peron, Thomas Facchini, Catherine Terret, David Coeffic

Crit Rev Oncol Hematol· December 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bevacizumab plus microtubule targeting agents in heavily pre-treated ovarian cancer patients: a retrospective study.
Irène Asmane, Jean-Emmanuel Kurtz, Agathe Bajard, Jean-Paul Guastalla, Pierre Meeus, David Coeffic

Bull Cancer· October 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Final results of ERASME-4: a randomized trial of first-line docetaxel plus either capecitabine or epirubicin for metastatic breast cancer.
Thomas Bachelot, Agathe Bajard, Isabelle Ray-Coquard, Jocelyne Provencal, David Coeffic

Oncology· September 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Node negative breast cancer. Beyond international consensus: a pragmatic approach].
Frédérique Penault-Llorca, David Coeffic, Thierry Delozier, Nadine Dohollou, Gilles Freyer

Bull Cancer· July 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Multicenter phase II trial of neoadjuvant therapy with trastuzumab, docetaxel, and carboplatin for human epidermal growth factor receptor-2-overexpressing stage II or III breast cancer: results of the GETN(A)-1 trial.
Bruno P Coudert, Remy Largillier, Laurent Arnould, Philippe Chollet, Mario Campone, David Coeffic

J Clin Oncol· July 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Stage-related changes in functional capacity in Hodgkin's disease: assessment by cardiopulmonary exercise testing before initiation of treatment.
Eric Page, David Assouline, Catherine Durand, Odile Brun, David Coeffic

Ann Hematol· December 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase II study of an oxaliplatin/vinorelbine/5-fluorouracil combination in patients with anthracycline-pretreated and taxane-pretreated metastatic breast cancer.
Thierry Delozier, Jean-Paul Guastalla, Alejandro Yovine, Christelle Levy, Philippe Chollet, David Coeffic

Anticancer Drugs· October 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cardiac dysfunction in clinical trials of trastuzumab.
Eric Page, David Assouline, Odile Brun, David Coeffic, Danièle Fric

J Clin Oncol· October 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Adjuvant therapy for breast cancer patients: treatment decision tree from a French cancer network].
Thomas Bachelot, Isabelle Ray-Coquard, David Coeffic, Hugues Barletta, Marie-Claude Gouttebel

Bull Cancer· October 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis